BRS3-FM3-PM8 - Eicosanoid / SPM Balance
(Shifting from Pro-Inflammatory to Calming Pro-Resolving Lipid Signals)
1. Mission & Overview
Mission
Shift lipid mediator balance from pro-inflammatory eicosanoids toward pro-resolving signals that terminate inflammation.
Overview
Balances arachidonic-acid-derived inflammatory eicosanoids against EPA/DHA-derived specialised pro-resolving mediators (SPMs, lipid signals that actively switch inflammation off rather than merely suppressing it). This mechanism governs the shift between pro-inflammatory and pro-resolving lipid signalling specifically, depending directly on essential fatty acid balance and antioxidant substrate sufficiency from upstream dietary intake. Because resolution is an active process rather than passive suppression, omega-3 status shapes whether inflammation terminates cleanly or persists.
- Balances pro-inflammatory eicosanoids against pro-resolving lipid mediators.
- Depends directly on essential fatty acid and antioxidant sufficiency.
- Drives active inflammation resolution rather than passive suppression.
2. Primary Biological Effects
↑ pro-resolving mediator bias; ↓ pro-inflammatory eicosanoid dominance
3. Phenome Connections
These mappings are translational relationships, not single-mechanism outcome claims. Phenomes are emergent functional patterns supported by multiple interacting PMs across the BRAIN Framework. Biology → Phenome Confidence reflects how directly this mechanism's biology would be expected to affect the phenome within BRAIN architecture — not dietary treatment efficacy. Evidence Confidence (below Key References) reflects how convincing the attached evidence is for the Biology → Phenome relationship on that row.
These are three independent scores. They are not combined or averaged. A phenome can have Medium registry evidence while individual mechanism rows show different Biology → Phenome and Evidence scores.
1. Phenome Evidence Confidence (Phenome Registry only)
Question: How convincing is the foundational evidence that this phenome is a valid, well-defined functional construct — and that diet-relevant biology can plausibly connect to it?
Not a roll-up of Biology → Phenome Confidence or Evidence Confidence from Primary Mechanism page rows. Those are scored per mechanism; this score is assigned once per phenome at registry level.
Derived from foundational landmark evidence organised in up to three layers: construct validation, biology→phenome linkage, and nutrition→biology modulation. Each layer may include one or many landmark papers depending on registry review.
2. Biology → Phenome Confidence (Primary Mechanism page §3 rows)
Question: If this PM/FM biology were substantially impaired in isolation, how directly would that phenome be expected to suffer — within BRAIN architecture?
How it is derived: Reviewers read the PM/FM definition and biological function first — initially ignoring attached references and whether dietary intervention studies exist. References are reviewed only when scoring Evidence Confidence (below).
Score levels (the value shown on each row as Biology → Phenome Confidence):
- High — primary biological determinant (e.g. noradrenergic signalling → attention; GABA synthesis → calming tone)
- Medium — major contributory determinant, not the sole driver
- Low–Medium — established but indirect, modulatory, or one integrative step removed
- Low — distal, conditional, or weak biological coupling
“Not dietary treatment efficacy” means this score does not ask whether a diet or supplement treats the phenome. It asks whether the biology itself is architecturally relevant. Limited dietary RCT evidence belongs in Evidence Confidence, not here.
3. Evidence Confidence (Primary Mechanism page §3 rows)
Question: How convincing are the attached Key References on that specific row that this biology actually relates to this phenome?
How it is derived: Assigned after Biology → Phenome Confidence, by reviewing only the references on that PM/FM row. Judges whether refs support the relationship — not just mechanism or phenome in isolation.
- High — strong convergent human evidence directly linking mechanism biology to phenome variation
- Medium — multiple human lines supporting the relationship; may include one bridge study with an inferential step
- Low–Medium — convergent translational stack without direct mechanism↔phenome measurement on the row
- Low — mechanistic or preclinical only; mechanism and phenome supported separately but not bridged
Often equal to or lower than Biology → Phenome Confidence. Can occasionally be higher when outcome evidence is stronger than the mechanism's contributory role.
- Biology → Phenome Confidence: Low–Medium
- Rationale: Specialized pro-resolving mediators actively terminate inflammation without suppressing immune surveillance — supporting cognitive clarity context through resolution-oriented lipid signalling.
- Key References:
- Evidence Confidence: Low–Medium
- Biology → Phenome Confidence: Low–Medium
- Rationale: Omega-3-derived resolution biology may modulate affective inflammatory context when EPA/DHA substrate and omega-6:omega-3 balance are adequate over habitual intake.
- Key References:
- Evidence Confidence: Low–Medium
- Biology → Phenome Confidence: Low
- Rationale: Resolution-phase lipid mediator balance may intersect attention-relevant inflammatory tone; direct ADHD SPM outcome evidence remains limited.
- Key References:
- Evidence Confidence: Low
- Biology → Phenome Confidence: Medium
- Rationale: Persistent inflammatory signalling and impaired resolution-phase lipid mediator balance are recognised contributors to anxious perseverative cognition within neuroimmune framing (Slavich & Irwin, 2014; Marsland et al., 2017). SPM-oriented resolution biology and human omega-3 intervention reduced inflammatory markers and anxiety symptoms alongside cytokine remodelling (Kiecolt-Glaser et al., 2011; Ferguson et al., 2014). This PM governs eicosanoid–SPM balance — not omega-3 treatment — and attached anxiety outcomes require one inferential step to PH016 rather than direct perseverative-thought measurement.
- Key References:
- Slavich & Irwin (2014) — Human Mechanistic
- Marsland et al. (2017) — Human Mechanistic
- Kiecolt-Glaser et al. (2011) — Human Outcome
- Ferguson et al. (2014) — Human Study
- Evidence Confidence: Medium
- Biology → Phenome Confidence: Low
- Rationale: Resolution-phase eicosanoid balance may modulate inflammatory tone intersecting reward-processing and depressive biology in translational framing; Gruber et al. (2023) reviews insulin–dopamine reward disruption in depression as adjacent context.
- Key References:
- Evidence Confidence: Low–Medium
4. Levers
Intervention Profile
Intervention Dominance: Diet-Dominant
- EPA/DHA ← oily fish, fish roe, algal oil
- Whole-diet fatty acid balance ← nuts, seeds, minimally processed fat sources
- Lower excess oxidized omega-6 load ← reduced fried and degraded oil exposure
- AA balance
- DHA
- EPA
- selenium
1. Food Preparation & Delivery ONLY
- Gentle cooking of marine-fat sources helps preserve EPA/DHA integrity for eicosanoid and SPM substrate supply — see Salmon — Preparation.
- Avoid rancid or repeatedly heated fish-oil matrices — preparation state affects the inflammatory lipid mediators this PM depends on.
- Repeated weekly marine-fat exposure matters more than isolated dosing.
- Soak or sprout phytate-rich seeds and legumes to improve plant zinc and mineral bioavailability.
- Lower inflammatory load from broader diet and lifestyle context helps preserve resolution capacity once substrate support is present.
5. Mechanistic Basis
Summary
Inflammation termination depends on lipid mediators that actively resolve rather than merely suppress immune activity. EPA and DHA substrate availability shapes whether signalling bias moves toward specialized pro-resolving mediators within BRS3(FM3) - Inflammation Resolution Capacity.
(Lipid mediator balance)
Inflammatory tone is shaped by the substrate pool available for eicosanoids and specialized pro-resolving mediators (SPMs). Resolution pathways are biochemically distinct from simple inflammatory blockade → [Serhan & Petasis, 2011]
(Fatty-acid substrate competition)
Arachidonic-acid-derived pro-inflammatory mediators and EPA/DHA-derived resolution pathways compete for enzymatic processing within shared lipid-signalling networks. Chronic omega-6 dominance or oxidized-fat exposure can skew mediator output → [Simopoulos, 2011]
(Boundaries of the mechanism)
Downstream cytokine-network readouts are handled by BRS3-FM3-PM7 - Cytokine Network Modulation. Membrane PUFA protection upstream belongs to BRS3-FM2-PM5 - Lipid Peroxidation Control. Transcriptional inflammatory control is represented by BRS3-FM1-PM1 - NF-kB Signalling Regulation.
(Integration within BRS3)
This PM anchors resolution-oriented lipid signalling within BRS3(FM3), supported by habitual EPA/DHA intake through §4.1 Direct Dietary Levers.
5.1 Evidence Highlights
Introduction/Summary
The SPM resolution framework is well established. The evidence below highlights active inflammation termination, omega-3 substrate dependence, and dietary fatty-acid balance.
- Confidence: low-medium
- Evidence Level: mechanistic
- Rationale: Specialized pro-resolving mediators derived from DHA and EPA actively terminate inflammation without suppressing immune surveillance — resolvins, protectins, and maresins inhibit neutrophil infiltration and support macrophage clearance [Serhan & Petasis, 2011].
- Key References:
- Confidence: low-medium
- Evidence Level: mechanistic
- Rationale: High-dose EPA+DHA attenuated fever and downstream cytokines in controlled endotoxemia while TNF-α remained unchanged — consistent with omega-3s reshaping the resolution phase rather than blocking inflammatory initiation [Ferguson et al., 2014].
- Key References:
- Confidence: low-medium
- Evidence Level: mechanistic
- Rationale: Evolutionary and dietary omega-6:omega-3 imbalance shifts lipid-mediator output toward pro-inflammatory eicosanoid dominance — the substrate-balance frame this PM operationalises [Simopoulos, 2011].
- Key References:
- Confidence: low-medium
- Evidence Level: mechanistic
- Rationale: Quercitrin anti-inflammatory effects may be augmented by co-ingestion of omega-3s and olive oil — supporting combined polyphenol–marine-fat patterns for resolution-oriented lipid signalling [Camuesco et al., 2006].
- Key References:
6. BRS Pathways and Connections
6.1 BRS Pathways
- None listed
6.2 Cross-BRS Mechanism Relationships
Primary Mechanisms in other Biological Regulatory Systems that directly interact with, constrain or support this mechanism.
- BRS1-FM3-PM6 — Neuronal Membrane DHA Incorporation — membrane long-chain PUFA substrate pools feeding specialized pro-resolving mediator formation
- BRS5-FM1-PM2 — LPS / Endotoxin Containment — gut endotoxin containment upstream of systemic cytokine network tone
- BRS5(FM1) — Gut Barrier Integrity and Immune Interface — gut–immune interface context influencing inflammatory resolution substrate availability
- BRS6(FM1) — Glycaemic–Insulin Stability & Cognitive Energy Availability — post-prandial glycaemic context conditioning inflammatory cytokine expression
6.3 Local BRS Mechanism Relationships
Related Primary Mechanisms within the same Biological Regulatory System that collectively support the integrated biological function.
- BRS3-FM3-PM7 — Cytokine Network Modulation — downstream cytokine readouts of resolution-oriented lipid signalling
- BRS3-FM2-PM5 — Lipid Peroxidation Control — upstream membrane PUFA integrity preserving SPM substrate quality
7. Scoreable Inputs & Modulation Signals
This PM is scoreable through omega-3 delivery and fatty-acid-balance signals relevant to inflammation resolution.
| Input Category | Example Inputs | PM6 Relevance |
|---|---|---|
| Functional Property Potentials | marine_omega3_pattern; fatty_acid_balance; lower_oxidized_oil_load | May support pro-resolving mediator bias. |
| Realised Functional States | oily_fish_pattern; balanced_pufa_context | Reflect practical SPM-supportive states. |
| Preparation Transformations | gentle_fat_cooking; lower_reused_oil_exposure | May help preserve lipid quality relevant to this PM. |
8. References
- Serhan and Petasis (2011) — Resolvins and Protectins in Inflammation Resolution
- Simopoulos (2011) — Omega-6/Omega-3 Ratio and the Brain
- Ferguson et al. (2014) — Omega‐3 PUFA Supplementation and the Response to Evoked Endotoxemia in Healthy Volunteers
- Camuesco et al. (2006) — Intestinal Anti-Inflammatory Activity of Quercitrin
- Kiecolt-Glaser et al. (2011) — A Randomized Controlled Trial
- Slavich & Irwin (2014) — From Stress to Inflammation and Major Depressive Disorder
- Marsland et al. (2017) — Systemic Inflammation and Resting State Connectivity of the Default Mode Network
- Gruber et al. (2023) — Impact of Insulin and Insulin Resistance on Brain Dopamine Signalling and Reward